President Trump has signed an executive order aimed at reducing research restrictions on psychedelics, including ibogaine, which is used in some countries for treating post-traumatic stress disorder (PTSD). The signing took place in the Oval Office, attended by notable figures such as Health and Human Services Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan. Trump stated that the order intends to “dramatically accelerate access to new medical research and treatments” involving these substances, which he described as having “life-changing potential.” The federal government will invest $50 million into psychedelic research and create pathways for using ibogaine for severely ill patients under the FDA’s Right to Try rule. FDA Commissioner Marty Makary announced that three psychedelics would be added to a national priority program to expedite drug reviews, and human trials for ibogaine will begin.
Why It Matters
This initiative reflects a growing interest in the potential therapeutic benefits of psychedelics, particularly for mental health conditions like PTSD and addiction. Ibogaine, classified as a Schedule I substance, has been associated with significant risks, including dangerous heart rhythm disturbances, which have resulted in fatalities. Historically, there has been a lack of large-scale clinical trials on ibogaine, with previous studies primarily being observational and small in scale. The federal government’s commitment to research funding and regulatory pathways could significantly shift the landscape for psychedelic therapies, particularly for veterans facing high rates of suicide and mental health challenges.
Want More Context? 🔎
